1. A phase 2a, randomized, double‐blind, placebo‐controlled, three‐arm, parallel‐group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF‐06835919 in patients with non‐alcoholic fatty liver disease and type 2 diabetes. Issue 4 (17th January 2023) Authors: Saxena, Aditi R.; Lyle, Stephanie‐An; Khavandi, Kaivan; Qiu, Ruolun; Whitlock, Mark; Esler, William P.; Kim, Albert M. Journal: Diabetes, obesity & metabolism Issue: Volume 25:Issue 4(2023) Page Start: 992 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗